Cancer incidence, mortality and survival trends in Canada, 1970-2007

Chronic Diseases and Injuries in Canada

Volumn 33, Issue 2, 2013, Pages 69-80

  Kachuri, L ^a   De, P ^a,b   Ellison, L F ^c   Semenciw, R ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Societe canadienne du cancer   (Canada)

^c HEALTH STATISTICS DIVISION   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Cancer surveillance; Incidence; Mortality; Risk factors; Survival

Indexed keywords

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; AGED; CANADA; CLASSIFICATION; EARLY DIAGNOSIS; FACTUAL DATABASE; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; STATISTICS; SURVIVAL; VERY ELDERLY; VITAL STATISTICS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; CANADA; DATABASES, FACTUAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; SURVIVAL ANALYSIS; VITAL STATISTICS;

EID: 84874668418     PISSN: 02288699     EISSN: 14818523     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto (ON): Canadian Cancer Society; 2011
2. Statistics Canada. Leading causes of death in Canada, 2009 [Internet]. Ottawa (ON): Minister of Industry; 2012 [cited 2012 Sept 19] [Statistics Canada, Catalogue No.: 84-215-X). Available from: http://www.statcan.gc.ca/bsolc/olc-cel/olc-cel?catno=84-215-x&lang=eng
3. Statistics Canada. Population projections for Canada, provinces and territories, 2009 to 2036 [Internet]. Ottawa (ON): Minister of Industry; 2010 [cited 2011 Aug 5]. [Statistics Canada, Catalogue No.: 91-250-X]. Available from: http://www.statcan.gc.ca /daily-quotidien/100526/dq100526b-eng.htm
4. Statistics Canada. Cancer incidence in Canada 2007 and 2008 [Internet]. Ottawa (ON): Minister of Industry; 2010 [cited 2011 Aug 5]. [Statistics Canada, Catalogue No.: 82-231- X]. Available from: http://www.statcan.gc.ca/pub/82-231-x/82-231-x2009001-eng.htm
5. Band P, Gaudette LA, Hill GB, Holowaty EJ, Huchcroft SA, Johnston GM, et al. The making of the Canadian Cancer Registry: cancer incidence in Canada and its regions, 1969-1988. Ottawa (ON): Canadian Council of Cancer Registries, Health and Welfare Canada, Statistics Canada, 1993
6. Statistics Canada. Demographic estimates compendium, 2010. CANSIM Table 051- 0001, released on September 29, 2010. Ottawa (ON): Minister of Industry; 2010
7. Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL. Comparability and quality control in cancer registration. Lyon (FR): World Health Organization; 1994
8. Fritz A, Percy C, Jack A, Shanmugarathan K, Sobin L, Parkin DM, et al., editors. International classification of diseases for oncology, 3rd ed. Geneva (CH): World Health Organization; 2000
9. International statistical classification of diseases and related health problems, 10th rev. Geneva (CH): World Health Organization; 1992
10. Joinpoint regression program, v.3.5.1 [computer program]. Rockville (MD): Statistical Research and Applications Branch, National Cancer Institute; 2011
11. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-51
12. Dickman PW. Estimating and modelling relative survival using SAS [Internet]. [Stockholm (SE)]: [publisher unknown]; [cited 2010 Jan 4]. Available from: http://www.pauldickman.com/rsmodel/sas_colon
13. LF, Gibbons L; Canadian Cancer Survival Analysis Group. Five-year relative survival from prostate, breast, colorectal and lung cancer. Health Rep. 2001;13(1): 23-34
14. R. La survie au cancer pour les nouveaux cas déclarés au Québec en 1992. Quebec (QC): Institut national de santé publique du Québec; 2002
15. Cancer Survival Statistics [Internet]. Ottawa (ON): Statistics Canada; 2011 [cited 2011 Jul 5]. [Statistics Canada, Catalogue No.: 82- 226-X]. Available from: http://www.statcan.gc.ca/pub/82-226-x/82-226-x2011001-eng.htm
16. Wang D, Tindall DJ. Androgen action during prostate carcinogenesis. Methods Mol Biol. 2011;776:25-44
17. Vainio H, Bianchini F, editors. Weight control and physical activity. Lyon (FR): International Agency for Research on Cancer; 2002. (Vainio H, editor. IARC handbook of cancer prevention; vol 6).
18. Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol Biol. 2009;472:191-215
19. Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer. 2010;46(14):2593-604
20. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8): 989-1003
21. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571-8
22. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109(6): 1192-202
23. Levy I. Prostate cancer: the epidemiologic perspective. Can J Oncol. 1994;4 Suppl 1:4-7
24. Statistics Canada. Canadian Community Health Survey, Cycle 4.1, 2007 [computer file]. Ottawa (ON): Health Statistics Division; 2007
25. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13): 1310-9
26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8
27. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91(12):1017-24
28. Nam RK, Klotz LH. Trends in prostate cancer screening: Canada. In: Ankerst DP, Tangen CM, Thompson IM, editors. Current clinical urology: prostate cancer screening, 2nd ed. New York (US): Humana Press; 2009. pp. 23-33
29. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60 (3 Suppl 1):7-11
30. Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys. 2003;57(3):629-34
31. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;(36):19-25
32. Shields M, Wilkins K. An update on mammography use in Canada. Health Rep. 2009;20(3):7-19
33. De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst. 2010;102(19):1489-95
34. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134
35. Alcohol consumption and ethyl carbamate. Lyon (FR): International Agency for Research on Cancer; 2010. (IARC monographs on the evaluation of carcinogenic risks to humans; vol 96).
36. Friedenreich C. The role of physical activity in breast cancer etiology. Semin Oncol. 2010;37(3):297-302
37. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20(7):1809-17
38. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002;94(21):1626-34
39. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975- 2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407-27
40. NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991; 265(3):391-5
41. Tobacco smoke and involuntary smoking. Summary of data reported and evaluation. Lyon (FR): International Agency for Research on Cancer; 2004. (IARC monographs on the evaluation of carcinogenic risks to humans; vol 83.)
42. Kleinsmith LJ, editor. Principles of cancer biology, 1st edition. San Francisco (CA): Benjamin Cummings; 2005
43. Reid J, Hammond D. Tobacco use in Canada: patterns and trends, 2011 edition. Waterloo (ON): Propel Centre for Population Health Impact, University of Waterloo; 2011
44. The Surgeon General's Advisory Committee on Smoking and Health. Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington (DC): US Department of Health, Education and Welfare, 1964. (Public Health Service Publication, No. 1103.)
45. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103(9):714-36
46. Food, nutrition, physical activity, and the prevention of cancer: a global perspective [Internet]. Washington (DC): World Cancer Research Fund/American Institute for Cancer Research; 2007 [cited 2012 Sept 19]. Available from: http://www.dietandcancerreport.org/cancer_resource_center/downloads/Second_Expert_Report_full.pdf
47. Tjepkema M. Adult obesity. Health Rep. 2006;17(3):9-25
48. Statistics Canada. Canadian Health Measures Survey: Cycle 1 data tables. Ottawa (ON): Minister of Industry; 2010
49. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 2007;67(15):7534-9
50. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603-7
51. Schatzkin A, Freedman LS, Dawsey SM, Lanza E. Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst. 1994;86(14): 1053-7
52. Pan-Canadian System Performance Working Group. 2010 system performance report. Toronto (ON): Canadian Partnership Against Cancer; 2010
53. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and ageperiod- cohort effects. Br J Cancer. 2001; 85(9):1335-9
54. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357-61
55. How J, Tabah R. Explaining the increasing incidence of differentiated thyroid cancer. CMAJ. 2007;177(11):1383-4
56. Butt P, Beirness D, Cesa F, Gliksman L, Paradis C, Stockwell T. Alcohol and health in Canada: a summary of evidence and guidelines for low-risk drinking. Ottawa (ON): Canadian Centre on Substance Abuse; 2011
57. CANSIM Table 105-0501. Health indicator profile, annual estimates, by age group and sex, Canada, provinces, territories, health regions (2011 boundaries) and peer groups, occasional [data file]. Ottawa (ON): Statistics Canada; [cited 2012 Sept 19]. Available from: http://www5.statcan.gc.ca/cansim/a05?lang=eng&id=1050501
58. Ahmad N, Flight J, Singh VA, Poole N, Dell CA. Focus on gender - a national survey of Canadians' use of alcohol and other drugs - Canadian Addiction Survey (CAS). Ottawa (ON): Health Canada; 2008
59. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Intl J Cancer. 2006;118(12):3030-44
60. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009;286(1):9-14
61. Solar and ultraviolet radiation. Lyon (FR): International Agency for Research on Cancer; 1992. (IARC monographs on the evaluation of carcinogenic risks to humans; vol 55.)
62. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93(9):678-83
63. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331(7515):481
64. The Ontario Sun Safety Working Group. Insight on cancer: sun exposure and protective behaviours in Ontario. An Ontario report based on the 2006 Second National Sun Survey. Toronto (ON): Canadian Cancer Society; 2010 [cited 2011 Jun 13]. Joint publication of Cancer Care Ontario. Available from: http://uvnetwork.ca /InsightonCancerSunExposureandProtective BehavioursinOntarioFinal.pdf
65. Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Holzel D, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011;131(3):719-26
66. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2008. Bethesda (MD): National Cancer Institute; 2011 [cited 2011 Dec 13]. Available from: http://seer.cancer.gov/csr/1975_2008/
67. Morton DL. Current management of malignant melanoma. Ann Surg. 1990;212(2): 123-4
68. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203-5
69. Leslie JA, Prihoda T, Thompson IM. Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. Urol Oncol. 2003;21(1):39-44
70. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305-11
71. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004; 159(3):259-68
72. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8(1):1-27
73. Schistosomes, liver flukes and Helicobacter pylori. Lyon (FR): International Agency for Research on Cancer; 1994. (IARC monographs on the evaluation of carcinogenic risks to humans; vol 61.)
74. Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer. 2001;11(1):24-31
75. National Advisory Committee on Immunization. Statement on human papillomavirus vaccine. Can Commun Dis Rep. 2007;33(2):1-32
76. A review of human carcinogens: biological agents. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC monographs on the evaluation of carcinogenic risks to humans; vol 100b.)
77. Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPVunrelated sites in a multicultural population: the British Columbia experience. Cancer. 2010;116(11):2635-44.